Company Profile
Protara Therapeutics Stock Price, News & Analysis
- Ticker:
- TARA
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
4.04 USD (+0.50%)
Close
Last updated: July 27, 2026
244M USD
Market cap
Why the stock is moving
As of Jul 27, 2026, TARA closed up 0.50% at $4.04. No new same-company headline was identified in the current news window.
Company overview
Business overview
Protara Therapeutics is a biotechnology company focused on rare disease and oncology programs, including metabolic and lymphatic disease. Its story centers on high-unmet-need conditions and a narrow pipeline.
Geographic Base and Sector Classification
Headquartered in the United States and listed on NASDAQ, Protara sits in specialty biotechnology.
Business Model Characteristics
The company depends on clinical data, dosing strategy, and the ability to build a focused rare-disease franchise.
Position Within the Biotechnology Landscape
Protara is a small-cap catalyst name whose valuation depends on early clinical milestones.
Future catalysts
Protara Therapeutics is heading into a more important stretch around TARA-002. Management's latest framing highlights The Company intends to submit a Biologics License Application (BLA) for TARA-002 in Lymphatic Malformations (LMs) in 2H 2027 Hosting virtual investor webinar discussing LMs.... The stock is likely to react most to whether those milestones keep moving without a reset.
Recent news
The five most recent related feed items are shown below in reverse chronological order.
- 01
GSK to establish new flagship R&D centre on Cambridge Biomedical Campus, UK
GSK · Source: GSK plc
- 02
Legend Biotech to Host Investor Conference Call on Second Quarter 2026 Results
LEGN · Source: Legend Biotech Corporation
- 03
- 04
- 05
Kymera Therapeutics Appoints Terence Rooney, MD, as Chief Medical Officer
KYMR · Source: Kymera
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Protara Therapeutics (TARA)?
Protara Therapeutics (TARA) most recently closed at 4.04 USD, a +0.50% move versus the previous session.
What is the market cap of Protara Therapeutics (TARA)?
Protara Therapeutics currently has a market capitalization of 244M USD on BioPharmSignal.
What does Protara Therapeutics do?
Protara Therapeutics is a biotechnology company focused on rare disease and oncology programs, including metabolic and lymphatic disease. Its story centers on high-unmet-need conditions and a narrow pipeline.
On which exchange is TARA stock listed?
Protara Therapeutics (TARA) is associated with NASDAQ, United States, Biopharma.
What is TARA-002?
Protara Therapeutics is heading into a more important stretch around TARA-002.
Which conditions is Protara Therapeutics targeting with TARA-002?
Protara Therapeutics is associated with oncology, rare disease, metabolic disease based on its company overview and current catalyst commentary.
How does Protara Therapeutics describe recent progress with TARA-002?
Protara Therapeutics is heading into a more important stretch around TARA-002.
What is Protara?
Protara Therapeutics is a biotechnology company focused on rare disease and oncology programs, including metabolic and lymphatic disease.